Coherus Assails Amgen's Neulasta Biosimilar Suit
Coherus Biosciences Inc. on Thursday told a Delaware federal court that its biosimilar application doesn't infringe an Amgen Inc. patent covering anti-infection drug Neulasta and that Amgen's infringement suit should be...To view the full article, register now.
Already a subscriber? Click here to view full article